HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic rejection: prospects for therapeutic intervention in fibroproliferative vascular disease.

Abstract
Vascular disease, manifesting as either transplant arteriopathy or native atherosclerosis, is currently the main obstacle to successful transplant outcome. In addition, vascular restenosis following balloon angioplasty or stenting continues to limit the long-term efficacy of these procedures. Neointimal hyperplasia is refractory to conventional immunosuppression although newer agents, such as rapamycin, have shown considerable promise in controlling it. By allowing large-scale study of gene expression during vascular remodelling, the emerging field of genomics is poised to revolutionise the drug discovery process. Here we summarise our initial experience using genomic methods to identify new targets for therapeutic intervention in vascular disease.
AuthorsPekka Häyry, Einari Aavik, Minnie Sarwal, Daniel du Toit, Joannis Vamvakopoulos
JournalExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation (Exp Clin Transplant) Vol. 1 Issue 1 Pg. 35-8 (Jun 2003) ISSN: 1304-0855 [Print] Turkey
PMID15859905 (Publication Type: Journal Article, Review)
Topics
  • Chronic Disease
  • Graft Rejection (etiology)
  • Humans
  • Organ Transplantation (adverse effects)
  • Vascular Diseases (complications, etiology, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: